Close

Lerdelimumab (TAB-100)

DESCRIPTION CATALOG # SIZE PRICE
Anti-Human TGF beta 2 Therapeutic Antibody TAB-100 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • Recombinant monoclonal antibody to TGF beta 2. Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery.
  • Target
  • TGF beta 2
  • Type
  • IgG4
  • Immunogen
  • An epitope of TGF beta 2 (Human).
  • Species Reactivity
  • Human
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in FuncS, IF, Neut, ELISA, FC, IP, ICC and most other immunological methods.
  • Specificity
  • Tested positive against native human antigen.
  • Protein Construction
  • Immunoglobulin G4,anti-(human transforming growth factor b2) (human monoclonal CAT-152 g4-chain), disulfide with humanmonoclonal CAT-152 l-chain, dimer
  • Purity
  • >95.0% as determined by analysis by RP-HPLC.
  • Size
  • 1mg
  • Storage
  • Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

BACKGROUND

  • Antigen Description
  • TGF-beta 2 has suppressive effects on interleukin-2 dependent T-cell growth.
  • Function
  • beta-amyloid binding; cytokine activity; growth factor activity; protein binding; contributes_to protein binding; protein heterodimerization activity; protein homodimerization activity; receptor binding; receptor signaling protein serine/threonine kinase
  • Synonyms
  • TGFB2; transforming growth factor, beta 2; transforming growth factor beta-2; G-TSF; cetermin; polyergin; BSC-1 cell growth inhibitor; glioblastoma-derived T-cell suppressor factor; TGF-beta2; MGC116892;

Related Products

Online Inquiry

Verification code
Click image to refresh the verification code.

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us